Loading insider details...
Beta
Latest Form 4 (Aug 10, 2026): Exercise/Conversion of 350,000 AKBA shares, $220.5K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 10, 2026 | Akebia Therapeutics, Inc. (AKBA) | Exercise/Conversion | 350,000 | $220.5K |
| Mar 5, 2026 | Akebia Therapeutics, Inc. (AKBA) | Purchase | 69,270 | $86.6K |
| Feb 4, 2026 | Akebia Therapeutics, Inc. (AKBA) | Sale | 46,660 | $64.9K |
| Feb 3, 2026 | Akebia Therapeutics, Inc. (AKBA) | Grant/Award | 743,000 | n/a |
| Mar 4, 2025 | Akebia Therapeutics, Inc. (AKBA) | Sale | 46,409 | $84.9K |
| Feb 4, 2025 | Akebia Therapeutics, Inc. (AKBA) | Grant/Award | 701,000 | n/a |
| Mar 1, 2024 | Akebia Therapeutics, Inc. (AKBA) | Sale | 46,570 | $73.6K |
| Feb 29, 2024 | Akebia Therapeutics, Inc. (AKBA) | Sale | 37,733 | $57.4K |
| Feb 2, 2024 | Akebia Therapeutics, Inc. (AKBA) | Grant/Award | 603,500 | n/a |
| Mar 3, 2023 | Akebia Therapeutics, Inc. (AKBA) | Sale | 38,259 | $33.6K |